Prestige Consumer Healthcare Closes LaCorium Deal, Raises $400M in Debt
Prestige Consumer Healthcare finalized its LaCorium Health buyout, priced $400M in senior notes, and set an August earnings date.
Prestige Consumer Healthcare (NYSE: PBH) had a busy Monday, dropping three big announcements at once: it officially closed its acquisition of LaCorium Health, locked in pricing on a $400 million senior notes offering, and told investors to mark August 6, 2026 on their calendars for first-quarter fiscal 2027 earnings.
The LaCorium deal had been telegraphed in advance, so the closing itself isn't a surprise — but pairing it with a fresh debt raise on the same day signals just how quickly Prestige is moving to fund this expansion. Senior notes, if you're not familiar, are a type of corporate bond that gets paid back before most other debt if things go sideways, making them relatively attractive to institutional buyers.
Read more Canada Diagnostic Centres Acquires Shift Imaging in Alberta →
Raising $400 million through a private debt offering is a meaningful move for a mid-cap consumer healthcare company. It suggests Prestige sees real strategic value in what LaCorium brings to the portfolio — enough to take on significant new liabilities to make it happen. LaCorium Health focuses on prescription and over-the-counter healthcare products, complementing Prestige's existing lineup of store-brand and branded consumer health items.
For everyday investors watching PBH, the August 6 earnings call will be the first real chance to hear management explain how LaCorium fits into the bigger picture — and whether the debt load looks manageable given current revenue trends. That report will cover the quarter ending around June 30, 2026, so it'll capture the very tail end of the pre-acquisition period.
Continue reading at GlobalNewswire.
